VM26 (NSC-122819): A clinical study in advanced cancer of the lung and ovary

This publication has 11 references indexed in Scilit:

• Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)
  Cancer, 1977
• VM 26 and VP 16–213: A comparative analysis
  Cancer, 1977
• Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.
  BMJ, 1975
• Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.
  The Journal of cell biology, 1975
• A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213
  Cancer, 1975
• Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas
  Cancer, 1974
• Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid Tumours
  BMJ, 1973
• Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors
  Published by Elsevier ,1973
• Clinical Screening of Epipodophyllotoxin VM26 in Malignant Lymphomas and Solid Tumours
  BMJ, 1972
• 4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action
  Published by Elsevier ,1970